Jim Simons
ZNTL icon

Jim Simons’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jim Simons’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54M Sell
1,938,145
-945,600
-33% -$2.44M 0.01% 1435
2025
Q4 		$3.89M Buy
2,883,745
+558,390
+24% +$813K 0.01% 1456
2025
Q3 		$3.51M Buy
2,325,355
+795,802
+52% +$1.19M ﹤0.01% 1693
2025
Q2 		$1.77M Buy
1,529,553
+703,512
+85% +$928K ﹤0.01% 2187
2025
Q1 		$1.31M Buy
826,041
+286,696
+53% +$618K ﹤0.01% 2238
2024
Q4 		$1.63M Sell
539,345
-17,599
-3% -$57.7K ﹤0.01% 2179
2024
Q3 		$2.05M Sell
556,944
-104,738
-16% -$381K ﹤0.01% 2002
2024
Q2 		$2.71M Buy
661,682
+399,745
+153% +$4.46M ﹤0.01% 1685
2024
Q1 		$4.13M Sell
261,937
-47,340
-15% -$651K 0.01% 1535
2023
Q4 		$4.69M Buy
309,277
+23,840
+8% +$348K 0.01% 1392
2023
Q3 		$5.73M Buy
285,437
+75,000
+36% +$1.9M 0.01% 1225
2023
Q2 		$5.94M Buy
210,437
+177,700
+543% +$4.26M 0.01% 1332
2023
Q1 		$563K Buy
+32,737
New +$663K ﹤0.01% 2819
2022
Q2 		– Sell
-109,337
Closed -$5.04M – 4631
2022
Q1 		$5.04M Buy
+109,337
New +$5.9M 0.01% 1585
2021
Q4 		– Sell
-31,337
Closed -$2.09M – 4277
2021
Q3 		$2.09M Buy
+31,337
New +$1.81M ﹤0.01% 2052
2021
Q1 		– Sell
-6,397
Closed -$332K – 3774
2020
Q4 		$332K Buy
+6,397
New +$289K ﹤0.01% 2995

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jim Simons's ZNTL Position: Q1 2026 in Review

Jim Simons reduced its Zentalis Pharmaceuticals (ZNTL) stake by 33% in Q1 2026, selling an estimated $2.44M and leaving 1,938,145 shares worth $4.54M. The position accounts for 0.01% of the portfolio, ranked #1435.

Jim Simons first reported a position in ZNTL in Q4 2020 and has held it in 16 quarters since. The position peaked at $5.94M in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Jim Simons held 1,938,145 shares of Zentalis Pharmaceuticals worth $4.54M as of Q1 2026.
  • Jim Simons sold 945,600 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $2.44M.
  • Zentalis Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1435 holding.
  • Jim Simons first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
  • Jim Simons's Zentalis Pharmaceuticals position peaked at $5.94M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.